Andrew J Pollard

Sir Andrew J Pollard serves as the Ashall Professor of Infection & Immunity at the University of Oxford and Director of the Oxford Vaccine Group. He concurrently holds positions as Consultant in Paediatric Infectious Disease at Oxford Children's Hospital, Fellow of St Cross College, and Chair of the UK Health Department's Joint Committee on Vaccination and Immunisation (JCVI). His work operates within the Department of Paediatrics at the University of Oxford, driving global vaccine research initiatives.

Pollard's research program centers on vaccinology and infectious disease immunology, with pioneering contributions to childhood immunisation and outbreak response. His team has led clinical development of vaccines for meningococcal disease, Ebola, influenza, typhoid, and SARS-CoV-2 through rigorous phase I-III trials. Notable achievements include establishing human challenge models for typhoid and demonstrating real-world vaccine impact in low-income settings, directly influencing WHO policy recommendations. Current work focuses on optimising immunisation schedules in resource-limited regions and developing next-generation vaccine platforms.

His 2025 publications reveal three critical research trajectories: evaluation of novel vaccine delivery technologies through public attitude metrics; cost-effectiveness modeling for respiratory virus vaccines in aging populations; and mechanistic studies of immune responses to pathogens like measles and typhoid. These works demonstrate his dual focus on immediate pandemic response and long-term vaccine infrastructure development across diverse global contexts.

Pollard's scientific recognition includes:

• Knighthood for exceptional contributions to vaccinology
• University of Oxford's Vice Chancellor's award for innovation (2020) for typhoid vaccine implementation

As Director of the Oxford Vaccine Group, Pollard commands substantial research funding from global health agencies and governments, enabling large-scale international trials across 50+ sites. His leadership in the Oxford-AstraZeneca COVID-19 vaccine program—which delivered 3 billion doses worldwide—exemplifies his capacity to rapidly mobilise multinational collaborations. While specific student mentorship isn't detailed, his group trains numerous clinical researchers through hands-on trial management in both UK and endemic settings.

The Oxford Vaccine Group maintains a 30-year research infrastructure spanning laboratory science, clinical trial units, and field sites in Nepal, Bangladesh, and Uganda. Current flagship projects include the TyVAC consortium evaluating typhoid conjugate vaccines in Africa and Asia, and the PneuCarriage study tracking pneumococcal transmission dynamics. Pollard's Kathmandu-based partnership with Patan Hospital serves as a model for sustainable research capacity building in low-resource environments.